Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.5702
+$0.0102 · +1.82%
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Latest quote
$0.5702
+$0.0102 · +1.82%
After-hours
$0.5702
$0.00 · 0.00%
Oct 9, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Day range
Current $0.5702
52-week range
Current $0.5702
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
57
Mixed
Risk
90
Extreme Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Day range
Current $0.5702
52-week range
Current $0.5702
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.06M USD | — | — | — | — |
| Gross profit | −1.06M USD | — | — | — | — |
| Research and development | 60.52M USD | 55.82M USD | 51.79M USD | 34.63M USD | 25.42M USD |
| Selling, general, and administrative | 18.94M USD | 20.42M USD | 17.08M USD | 16.57M USD | 11.41M USD |
| Operating expenses | 79.46M USD | 76.24M USD | 68.86M USD | 51.2M USD | 36.83M USD |
| Interest income | 1.74M USD | 5.06M USD | 5.2M USD | 701K USD | — |
| Depreciation and amortization | 1.06M USD | 1.37M USD | 1.11M USD | 975K USD | 377K USD |
| Operating income | −80.52M USD | −76.24M USD | −68.86M USD | −51.2M USD | −36.83M USD |
| Net income | −75.8M USD | −71.27M USD | −64.47M USD | −37.69M USD | −30.64M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$2.50
338.44% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 4, 2024 | 1:10 | — | — |
Effective Jan 4, 2024
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
